Log In
Print this Print this

SynCon DNA prostate cancer vaccine (INO-5150)

  Manage Alerts
Collapse Summary General Information
Company Inovio Pharmaceuticals Inc.
DescriptionDual-antigen DNA prostate cancer vaccine targeting PSA and PSMA synthetic consensus immunogens based on human and monkey sequences
Molecular Target Prostate-specific antigen (KLK3) (PSA) ; Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII)
Mechanism of Action 
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPreclinical
Standard IndicationProstate cancer
Indication DetailsTreat prostate cancer
Regulatory Designation


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today